Filing search / Nkarta, Inc. / "Mission"

8-K

EX-99.1

NKTX Nkarta, Inc.

16 Jul 24

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

6:30am

to personal family and health reasons. “James’ work has greatly contributed to the advancement of our science and mission. We are extremely grateful

8-K

EX-99.1

NKTX Nkarta, Inc.

27 Jun 24

Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis

6:45am

nephritis and the IND clearance for three additional indications are critical milestones in our mission to improve the accessibility and safety of cell

8-K

EX-99.1

NKTX Nkarta, Inc.

13 Jun 24

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

4:22pm

autoimmune diseases,” Vratsanos said. “Nkarta’s mission is my own. My passion is the translation of innovative immune science into approved therapies

8-K

EX-99.1

NKTX Nkarta, Inc.

17 Oct 23

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

7:06am

will be departing Nkarta. I thank each of them personally for their dedication to Nkarta and our mission to bring accessible and life-changing cell

8-K

EX-99.1

NKTX Nkarta, Inc.

5 Jul 23

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

4:09pm

manage our cash resources, and augment our growth by managing current partnerships and assessing new ones.” “It’s an honor to join a mission-driven

8-K

EX-99.1

npmrj

9 Nov 22

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

4:03pm

8-K

EX-99.2

7tv2uqjssx3

25 Apr 22

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

7:52am

10-K

c1y0fjjvt

25 Mar 21

Annual report

12:00am

8-K

EX-99.1

4mt1 8y530

14 Jul 20

Amendments to Articles of Incorporation or Bylaws

4:10pm